May 4, 2020 | Business Wire

Cerveau Technologies, Inc. Announces Collaboration with University College of London

BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading...

March 20, 2020 | Business Wire

Cerveau Technologies, Inc. Announces Collaboration with Alector, Inc.

BOSTON–(BUSINESS WIRE)–Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide...

November 14, 2019 | Business Wire

Cerveau Technologies, Inc. Announces Initiation of Japanese Phase I Study

KNOXVILLE, Tennessee--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced that the first healthy volunteer was injected and scanned...

September 27, 2019 | Business Wire

Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda),...

May 19, 2019 | Business Wire

Cerveau Technologies, Inc. Announces a Partnership with LuMind IDSC Foundation to Study Accumulation of Neurofibrillary Tau in Down Syndrome

BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC)...

March 22, 2019 | Business Wire

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable...

February 19, 2019 | Business Wire

Cerveau Technologies, Inc. and Institut de Radiofarmacia Aplicada de Barcelona, S.L. Announce Agreement to Manufacture Investigational Tau Ligand

BARCELONA, Spain--(BUSINESS WIRE)--This week Institut de Radiofarmacia Aplicada de Barcelona, S.L. (IRAB), a leading producer of...

December 13, 2018 | Business Wire

Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease

BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced that the Memory Aging and Cognition Centre (MACC) at the...

September 24, 2018 | Business Wire

Cerveau Technologies Inc. Signs Research Agreement with Ionis Pharmaceuticals, Inc. for Novel Tau Imaging Agent

BOSTON, Mass.--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Ionis Pharmaceuticals, Inc. for...